P27Kip1 (p27) blocks cell proliferation through the inhibition of cyclin-dependent kinase 2 (cdk-2). Despite robust expression in the heart, little is known about the regulation and function of p27 in this terminally differentiated tissue. Previously, we demonstrated that p27 exerts anti-apoptotic and growth-inhibitory effects through interaction with casein kinase 2 (ck2) in neonatal rat cardiomyocytes. Here, we test the hypothesis that delivery of a transactivator of transcription (TAT)-p27 fusion protein (TAT.p27) will improve cardiac function and survival in a rat model of myocardial infarction (MI).
Introduction
Ischaemic heart disease remains a major cause of death and disability in the developed world, with myocardial infarction (MI) from acute coronary artery occlusion representing a common underlying mechanism. Further damage via reperfusion injury and resultant apoptosis ultimately leads to extensive cardiomyocyte loss and subsequent ventricular remodelling and compensatory hypertrophy. 1 We previously reported that the cyclin-dependent kinase 2 (cdk-2) inhibitor p27Kip1 (p27) functions in the mouse heart to inhibit hypertrophic responses to ageing, angiotensin-II infusion, and transverse aortic banding. 2 Hypertrophy in these models was mediated by casein kinase 2 (ck2-a')-dependent phosphorylation and subsequent proteolytic degradation of p27. However, if carried to extreme, e.g. in the genetic absence of p27, mice suffer a dilated cardiomyopathy (DCM), progressive heart failure (HF), and death in response to hypertrophic stimuli. 2 Our previous in vitro work showed that p27 also inhibits apoptosis in hypoxic neonatal rat ventricular myocytes by inactivating Rb-E2f-dependent gene transcription. 3 Together, these studies have implicated p27 as a regulator of cardiac growth and survival in mouse and rat models of hypertrophy.
In the human heart, p27 expression increases by 25 weeks of foetal life and remains constant thereafter. 4 However, in patients with both acute and end-stage HF, p27 levels have been reported to fall. 4 In rat as well, levels of p27 increase between Days 12 and 15 of neonatal life and remain elevated throughout subsequent development. 4 Given these findings, and our earlier results, we hypothesized that p27 could be used as a therapeutic agent to limit apoptosis and prevent adverse hypertrophic remodelling following MI. To test this, we employed a transactivator of transcription (TAT).p27 fusion protein designed to facilitate transport of p27 across cell membranes, 5 to increase cardiac p27 levels following experimental MI in rodents. 6 Briefly, anaesthesia with isoflurane (5% induction, 2% maintenance) preceded intubation and ventilation. Adequacy of anaesthesia was monitored by loss of reflexes, and degree of muscle relaxation. Left-sided thoracotomy was performed between the fifth and sixth ribs. The pericardium was opened, and the heart exteriorized. The coronary artery was localized 1 -2 mm below the junction of the pulmonary conus and the left atrial appendage. A 5.0 silk suture was used to permanently constrict the artery from the left border of the pulmonary conus to the right border of the left atrial appendage. The heart was returned to the chest, and lungs were re-expanded before closing the chest wall with 4.0 silk. Sham animals underwent every procedure except coronary artery ligation.
Methods

Induction of MI
Construction of recombinant TAT.p27 fusion protein
cDNAs for p27 (Genbank D86924) and LacZ were cloned in the pRSETbased pTAT vector (kind gift from S. Dowdy, Howard Hughes Medical Institute, La Jolla, CA, USA) providing the N-terminal HIV-1 TAT protein transduction domain and an His-tag for purification and isolation. 5 
Western blot
Total protein extracts were prepared by homogenizing ventricular tissue in lysis buffer (1% SDS v/v, 1 mM PMSF, and 10 mg /mL aprotinin) and stored at 2208C. The protein content was determined using the bicinchoninic assay method (Pierce). Equal amounts of protein were boiled with SDS buffer, loaded on 6-12% denaturing polyacrylamide gels, blotted onto PVDF membrane. After blocking with 5% skimmed milk, specific primary antibodies were used as follows: p27 (1:1500; BD), transforming growth factor-b (TGF-b) (1:1000); Bcl-2 (B-cell Lymphoma 2) (1:1000), cleaved caspase 3 (1:2500), all from (Cell Signaling); Collagen III (1:10000; Abcam), and Atrial Natriuretic Peptide (ANP) (1:2500; Santa Cruz). Immunoblots were visualized by enhanced chemiluminescence, and quantified for specific protein content by densitometry with normalization for housekeeping genes GAPDH (1:2000; Sigma) and b-tubulin (1:1000; Cell Signaling).
Cardiac levels of TAT.p27 fusion protein
Hearts from 8-week-old wild-type (WT) mice were collected before (baseline) and at 5, 30, 60 min after iv delivery of TAT.p27 (20 mg/kg). Hearts were also collected at the same time points and processed for western blot (WB). Immunoblotting for TAT.p27 was performed as described above using an anti-HA (1:2000; Invitrogen) or anti-His antibody (1:2000; BD). In a separate set of experiments, hearts were collected from mice injected with TAT.p27 or saline at the above time points and processed for immunohistochemistry (IHC) for total p27 and His-tagged p27. Hearts were flushed clean of blood, excised, and fixed in 10% paraformaldehyde (PFA) for 20 min, followed by 1 h incubation in 0.1 M glycine and overnight incubation (at 48C) in 0.6 M sucrose. Samples were embedded in optimal cutting medium (OCT, Electron Microscopy Sciences), frozen on dry ice and stored at 2208C. Sections (3-5 mm) were cut and captured on positive charged ProbeOn Plus microscope slides (Fisher) and stored at 2208C. Following removal of OCT medium and permeabilization of sections with 0.5% Triton X, and 0.5% sodium citrate, sections were blocked for 1 h in 1% BSA and probed with His monoclonal antibody (1:100; Invitrogen) and a-sarcomeric actin (1:200; Sigma), cytochrome c (1:100; Cell Signaling). Secondary biotinylated polyclonal antibodies (Invitrogen) were used at the recommended dilution and incubated on sections for 1 h at room temperature. Nuclei were counter stained with 4, ′ 6 ′ diamidino-2-phenylindole (DAPI). Sections were mounted with low viscosity aqueous fast drying medium (DAKO), and imaged on an epifluorescence inverted microscope with AxioVision Imaging System (Zeiss MicroImaging, Germany).
Cardiac function assessment by echocardiography and pressure volume measurements
Experimental animals were anaesthetized with 3% isoflurane and assessed by echocardiography as previously described. 7 Following 48 h recovery, animals were subjected to identical anaesthesia for haemodynamic evaluation. Intubated animals were secured in a recumbent position on a heating pad (378C) and pressure-control ventilated on a 683 ventilator (Harvard Apparatus) at 45 breaths per min. Hearts were transapically instrumented with a 1.9F pressure-volume catheter (SciSense) as described. 8 
Histology and immunofluorescence
Rat hearts were collected at 28 days post-MI fixed with buffered 10% PFA for 1 h, followed by 1 h incubation in 0.1 M glycine and overnight incubation at 48C in 0.6 M sucrose. Samples were embedded in OCT and sections (3-5 mm) were cut and stored in 2208C. Sections for Masson-trichrome were processed as per manufacturer instructions (Sigma), with minor modifications staining. In a separate set of IHC experiments, rat heart sections were permeabilized and blocked for 1 h in 1% BSA and probed with primary polyclonal antibodies to a-sarcomeric actin (1:100; Sigma), wheat germ hemagglutinin (WGA) (1:100), and anti-His (1:100) (both from Invitrogen). Secondary antibodies (1:200; Invitrogen) were used at the recommended dilution and incubated on sections for 1 h at room temperature. Nuclei counterstained with (DAPI). Images were acquired on an inverted epifluorescent microscope (Zeiss).
TUNEL staining
Apoptotic nuclei were detected by in situ, terminal deoxynucleotidyl transferase-mediated digoxigenin-conjugated dUTP nick-end labelling (TUNEL), using an In Situ Cell Apoptosis Detection Kit (Roche) using frozen sections of heart (5 mm).
Statistical analysis
Data are presented as mean values + SD. Statistical analyses included Student's t-test and One-way ANOVA followed by Tukey and Bonferroni's multiple Therapeutic potential of p27 in myocardial infarction comparison post-tests. Avalue of P , 0.05 was taken to indicate statistical significance. The log-rank test was used to compare survival post-MI. All statistical analyses were performed on Graph Pad version 4.0 (La Jolla).
Results
Regulation of cardiac p27 levels after MI
To assess levels of p27 expression after MI, we performed WB on left ventricular protein extracts obtained from WT C57BL6 male mice (age 8 -10 week) at 0, 3, 7, 21, and 28 days post-LAD ligation. GAPDH-normalized levels of p27 were reduced by 35 and 48% on post-MI Days 21 and 28, respectively, when compared with baseline (P , 0.05 for both comparisons; Figure 1A ).
Genetic absence of p27 increases cardiac apoptosis, infarct size with reduced survival post MI
At 28 days post-MI, histology revealed significantly larger infarcts in p27KO when compared with WT mice (48 vs. 29%; P , 0.05; Supplementary material online, Figure SA1 ). In a separate group of animals, the presence of the apoptotic marker cytochrome c at 30 min post-LAD ligation was greater in p27KO mice than WT controls (11 + 0.5 vs. 2 + 0.5; cytochrome c positive cells/mm 2 , P , 0.05; Figure 1B ). Following MI, p27KO mice also manifest reduced survival when compared with WT mice (31 vs. 61%; P , 0.05; Figure 1C ). Of interest, the survival curves separated dramatically within 7 days of experimental MI, suggesting a critical role for p27 at this early stage.
Delivery of TAT.p27 fusion protein
To demonstrate transduction of heart tissue in vivo, His-and HA-(double)-tagged TAT.p27 fusion protein or saline was injected via the jugular vein. Mice were euthanized at 5, 30, and 60 min, and thereafter their hearts harvested for WB for total p27 or IHC was carried out for His-tagged p27. WB analysis showed that the levels of p27 are increased at 30 min post-iv injection and remained elevated above baseline at 60 min ( Figure 2A) . IHC on frozen heart sections revealed the highest levels of anti-His signal at 60 min ( Figure 2B ) and confirmed nuclear targeting of TAT.p27 ( Figure 2C ). These data suggest that the higher levels of total p27detected by WB at 30 min may reflect intravascular or interstitial TAT.p27, whereas the cellular uptake of TAT.p27 is greatest at 60 min.
Treatment with TAT.p27 improves cardiac function and haemodynamics
Next, echocardiography was used to examine cardiac structure and function in rats undergoing experimental MI and treatment with TAT.p27, TAT.LacZ, or saline control ( Figure 3A) . At baseline, no differences between the groups were observed ( Figure 3B , C, and E). In saline controls, fractional shortening (FS) declined from 49. Figure 3B ). TAT.p27 treatment prevented both an increase in LVEDD observed in TAT.LacZ-and saline-treated controls ( Figure 3C ) and progressive thinning of the anterior wall ( Figure 3D ). The loss of contractile performance [stroke volume (SV)], and an increase in LVEDP, observed in control animals was also limited by TAT.p27 ( Figure 3F ).
Scar size, fibrosis, and hypertrophy are improved by TAT.p27
Treatment with TAT.p27 reduced the infarct size, fibrosis, hypertrophy, and scar remodelling post-MI. Morphometric analysis of midventricular cardiac tissue sections revealed protective effects of TAT.p27. Histologically defined loss of LV free wall thickness was significantly prevented by TAT.p27, as was the increased LV perimeter and the scar area observed in TAT.LacZ-or saline-treated controls ( Figure 4A -C) . The extent of cardiac fibrosis was evaluated by Masson-trichrome staining at 28 days post-MI (Supplementary material online, Figure SB1 ; upper panels). The increase in the HW:BW ratio was reduced in animals treated with TAT.p27 when compared with controls ( Figure 4D ). At Day 10 post-MI, we performed WB on left ventricular protein extracts to detect markers of fibrosis such as TGF-b and Collagen III. Levels of TGF-b were 3 and 2.4 times higher in TAT.LacZ and saline controls, respectively, when compared with TAT.p27-treated animals (P , 0.05 for both; n ¼ 4). Levels of collagen III were 3.8 and 3.3 times greater in TAT.LacZ-and salinetreated control groups vs. TAT.p27-treated animals (P , 0.01 for both; n ¼ 4). Analysis of the LV cardiomyocyte size was undertaken using high magnification microscopy (Supplementary material online, Figure SB1 ; lower panels) to quantify circumference ( Figure 5A ) and the crosssectional area ( Figure 5B and C ) . These data show that treatment with TAT.p27 prevented cardiac remodelling when compared with TAT.LacZ and saline (P , 0.001 for all comparisons; n ¼ 6). Moreover, WB documented ANP levels in LV tissue homogenates were 1.5 and 1.9 times higher in TAT.LacZ and saline groups than following TAT.p27 (P , 0.01 and P , 0.05, respectively; n ¼ 4; Figure 5D ). Therapeutic potential of p27 in myocardial infarction 3.6 TAT.p27 treatment reduces apoptosis, increases survival post-MI Quantitative analysis of apoptosis by TUNEL staining was performed in sham rats and at 48 h post-MI in TAT.p27-, TAT.LacZ-, and salinetreated groups. This revealed 1.9 and 2.7 times greater cardiomyocyte apoptosis in saline-and TAT.LacZ-treated controls when compared with TAT.p27 (P , 0.01 and P , 0.05, respectively; n ¼ 9; Figure 6A and B). Consistent with this, WBs for cleaved caspase 3 and Bcl-2 revealed less post-MI apoptosis in TAT.p27-treated animals (P , 0.05 for both; Figure 6C and D). Most importantly, these molecular, functional, and structural differences translated into improved survival of animals treated with TAT.p27 vs. TAT.LacZ (86 vs.60%; P , 0.05; log-rank test; Figure 6E ).
Discussion
In the present study, we demonstrate that TAT.p27 fusion protein administered iv is taken up by the rodent heart in vivo, and results in significant reduction in apoptosis, infarct size, subsequent fibrosis, and mortality post-MI. Putting these findings together with the adverse cardiac remodelling and increased mortality observed in p27KO mice, our study reveals an important role for p27 in cardiac repair post-MI. Although it is tempting to speculate that treatment with TAT.p27 may rescue the phenotype of p27KO mice, our initial studies with this novel therapeutic agent have been restricted to supplementing endogenous cardiac p27 levels in the WT rat. Currently, only the rat MI model enables us to administer the volumes required (4 mL) for the effective dose of TAT.p27 (20 mg/kg). Further concentration of the TAT.p27 fusion protein will be required to deliver the much smaller volumes tolerated by mouse.
Our data show that endogenous cardiac levels of p27 levels begin to decline from baseline levels as early as 3 days post-MI, which achieve statistical significance by Days 21 and 28 post-MI. Of interest, similar observations were made in human HF. 4 Consistent with a critical role for p27 in the earliest stages post-MI, p27KO mice show diminished survival as early as Day 2 post-MI, when compared with WT. Additionally, cardiac apoptosis, as measured by cytochrome c activity, was significantly greater in p27KO vs. WT mice at the earliest stages following ischaemia. Together, these data led us to hypothesize that declining cardiac levels of p27 post-MI represent a therapeutic opportunity.
In the rodent heart, cardiomyocyte apoptosis in the area of ischaemic damage can occur for several days post-MI. 9 Later, during chronic LV remodelling, apoptosis may persists for up to 6 months, and is associated with progressive LV dilatation and impaired systolic function. 9 Apoptosis may also contribute to early structural alterations known to occur within the infarct area, namely cardiomyocyte loss, slippage, and elongation. 10 In our study, p27KO mice manifest early enhanced activation of cytochrome c, the inner mitochondrial membrane protein involved in the initiation of intrinsic apoptosis. Given this rapid onset of post-MI apoptosis (and mortality) observed in p27KO mice, we elected to treat the rat model at these same stages (Days 1 and 7 post-MI). The finding that these treatments achieved reductions in apoptosis that translated into less adverse remodelling and improved survival validates our conceptual approach. This report joins a growing body of evidence supporting the importance of apoptosis, and the potential of therapies targeting this process, in the pathophysiology of MI. For example, Gustafsson et al.
11 used a distinct TAT-conjugated apoptosis repressor with caspase recruitment domain (ARC) as an ex vivo therapy in the isolated rat heart global ischaemia-reperfusion model to demonstrate that preventing apoptosis was cardioprotective and limited infarct size. This group also delivered a distinct TAT-conjugated inhibitor of apoptosis, namely a dominant negative Bnip3 mutant, in the same ex vivo Langendorff model to demonstrate that preserving mitochondrial integrity also limited infarct size and improved cardiac function. 12 Finally, we previously showed in mice with the genetic absence of the anti-apoptotic gene growth differentiation factor-5, that additional decreases in the cardiac levels of expression of anti-apoptotic genes Bcl2 and Bcl-xL were associated with larger infarcts and greater subsequent scar expansion in a permanent LAD occlusion model of MI and chronic ischaemia in vivo. 6 Taken together, the above studies along with the loss-of-function (p27KO) and gain-of-function (TAT.p27) results provided by the current investigation represent compelling rationale for further preclinical and clinical translation of anti-apoptotic strategies for both ischaemia-reperfusion and MI. It remains uncertain as to what extent our use of TAT.p27 post-MI exerted its beneficial effects by preventing apoptosis or by preventing hypertrophy. As previously shown, p27 also functions in the mouse heart to inhibit hypertrophic responses to ageing, angiotensin-II infusion, and transverse aortic banding. Therapeutic potential of p27 in myocardial infarction among these are the abundant preclinical and clinical data supporting the use of inhibitors of the renin -angiotensin -aldosterone system to prevent hypertrophy (as well as fibrosis) and adverse remodelling post-MI. Two specific examples in rodent models similar to ours are worth mentioning. Using transgenic mice with overexpression and knockout of S100B, Tsoporis et al. 13 showed that this intrinsic negative regulator of myocardial hypertrophy modulated adverse remodelling by regulating the hypertrophic response. In a particularly unique non-cardiac approach, Lymperopoulos et al.
14 used a peptide inhibitor of adrenal beta-arrestin 1 to attenuate post-MI remodelling in the rat by reducing circulating aldosterone levels at 2 weeks post-MI. Given the above, we are not able to exclude the possibility that TAT.p27 exerted some of its benefits by preventing hypertrophic signalling in the heart. Having said this, the timing of TAT.p27 delivery used in our study (Days 1 and 7 post-MI) leads us to believe that most of the beneficial effects were driven by early prevention of apoptosis. Future studies, delivering TAT.p27 at later stages post-MI, may be able to address this question more specifically. In 1999, Poolman et al. 15 reported that the genetic deletion of p27 results in a significant increase in cardiomyocyte cell number and smaller cell size in hearts of adult p27KO mice, without compensatory increases in the expression of other cdk inhibitors. When Liao et al. 16 over-expressed cdk-2 in the transgenic mouse heart, they promoted the development of smaller, less differentiated mononuclear cardiomyocytes with increased DNA synthesis and PCNA expression. Together, these data suggested that p27 played a key role in blocking the cardiomyocyte cell cycle and, by extension, in limiting the regenerative capacity of the heart. If so, loss of p27 might have been expected to improve cardiac repair following injury. Indeed, this concept was indirectly supported by a study in which adenoviral delivery of cyclin A2 was shown to induce myocardial regeneration and enhance cardiac function in the rat LAD ligation model of heart failure. 17 Contradicting this premise, our study shows that the genetic absence of the cell cycle inhibitor p27 is deleterious post-MI, and that delivery of a p27 fusion protein exerts a cardio-protective effect post-MI. As such, our study provides new insights into the central role played by p27 in balancing cardiomyocyte cell proliferation, apoptosis, and hypertrophy; highlighting, in particular, the fact that specific cell cycle inhibitors may have unanticipated benefits following cardiac injury. 
